Background: Mutations in the long noncoding RNA RNase component of the mitochondrial RNA processing endoribonuclease (RMRP) give rise to the autosomal recessive condition cartilage-hair hypoplasia (CHH). The CHH disease phenotype has some overlap with dyskeratosis congenita, a wellknown ''telomere disorder.'' RMRP binds the telomerase reverse transcriptase (catalytic subunit) in some cell lines, raising the possibility that RMRP might play a role in telomere biology.
Objective: We sought to determine whether a telomere phenotype is present in immune cells from patients with CHH and explore mechanisms underlying these observations. Methods: We assessed proliferative capacity and telomere length using flow-fluorescence in situ hybridization (in situ hybridization and flow cytometry) of primary lymphocytes from patients with CHH, carrier relatives, and control subjects. The role of telomerase holoenzyme components in gene expression the Clinic for Special Children, Strasburg; c and activity were assessed by using quantitative PCR and the telomere repeat amplification protocol from PBMCs and enriched lymphocyte cultures. Results: Lymphocyte cultures from patients with CHH display growth defects in vitro, which is consistent with an immune deficiency cellular phenotype. Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH. Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH. Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes. Conclusion: These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism. (J Allergy Clin Immunol 2017;140:1120-9.)
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Cartilage-hair hypoplasia (CHH; [MIM: 250250] ) is an autosomal recessive condition characterized by metaphyseal dysplasia, bone marrow failure, increased risk of hematologic malignancy, and variable immunodeficiency. In particular, patients with CHH can have severe combined immunodeficiency and/or susceptibility to pathogens typically cleared by T-cell and natural killer (NK) cell-mediated mechanisms, such as the Herpesviridae varicella zoster virus, EBV, or human herpes virus 6. Mutations in the long noncoding (lnc) RNA component of the mitochondrial RNA processing endoribonuclease gene (RMRP; encoded on chromosome 9p) 1,2 or its regulatory elements cause CHH. At present, the dominant molecular mechanisms underlying the CHH phenotype are not clearly defined; however, some disease manifestations and risk factors described in patients with CHH overlap with those of patients with known telomere deficiency diseases, such as dyskeratosis congenita. [3] [4] [5] RMRP has been shown to have several important molecular functions, including processing of mitochondrial RNA, cleavage of ribosomal RNA, and cleavage of specific mRNAs to their active form, including cyclin B2. All these known functions can both individually and collectively impair cellular metabolism, cellular function, and proliferation when RMRP is mutated (reviewed by Thiel and Rauch 6 ). Furthermore, several independent reports have implicated RMRP binding to the telomerase reverse transcriptase (catalytic subunit) [TERT]), [7] [8] [9] potentially associating RMRP function with telomere homeostasis.
Telomeres consist of G-rich DNA repeats and bound proteins at the end of linear chromosomes that effectively provide a protective ''capping'' structure preventing activation of DNA damage and repair responses. Telomere length in human cells and cell types is heterogeneous, and loss of telomere repeats was shown to occur with cell division and age. Replicative senescence or apoptosis caused by short telomeres has been clearly demonstrated, and critical loss of a few telomeres or telomere molecular uncapping (which can be seen in the absence of global telomere length compromise) has been implicated in genomic instability and neoplastic transformation, as well as in several age-related diseases (reviewed by Aubert and Lansdorp
10
).
Unlike the majority of somatic cells, lymphocytes upregulate telomerase expression at specific developmental stages, as well as in response to antigen receptor or cytokine stimulation. 11, 12 This selective and controlled activation of expression peaks 3 days after in vitro antigen receptor stimulation and has been shown to support the telomere length maintenance and proliferative potential of these cells, both of which are essential to sustaining appropriate cell lineage development, cell division, and clonal expansion inherent in immune function. 12, 13 We investigated the telomere length, telomerase activity, and disease status of 15 patients with CHH and 8 haploinsufficient carriers from 6 families with CHH, all carrying the common founder mutation RMRP n.70A>G. In vitro proliferative capacity of primary lymphocytes and telomerase molecular parameters were examined to further characterize the cellular immune phenotype and telomere biology phenotype correlated with specific genotypes in heterozygote carriers and patients with CHH.
METHODS

Ethical statement and patients' characteristics
All samples from patients with CHH and their relatives were obtained with informed consent and approval of local ethical review boards in accordance with the Declaration of Helsinki. The patients were cared for at the Clinic for Special Children in Strasburg, Pennsylvania. Clinical and molecular studies were performed with oversight from the Lancaster General Hospital Institutional Review Board. All reported subjects underwent laboratory and molecular testing, as previously described. 14 The patients had clinical examination features consistent with the metaphyseal dysplasia classic for CHH and were found to have homozygous lncRNA RMRP n.70 A>G variants.
Telomere length measurements using flowfluorescence in situ hybridization and statistics
Telomere length measurements with flow-fluorescence in situ hybridization (flow-FISH) was performed, as previously described. 15 Briefly, white blood cells were isolated by means of osmotic lysis of erythrocytes in whole blood with NH 4 Cl. The white blood cells were then mixed with bovine thymocytes of known telomere length (which serve as an internal control), denatured in formamide at 878C, and hybridized with a fluorescein-conjugated (CCCTAA) 3 peptide nucleic acid probe specific for telomere repeats and counterstained with LDS751 DNA dye. The fluorescence intensity in granulocytes, total lymphocytes, and lymphocyte subsets defined by labeled antibodies specific for CD20, CD45RA, and CD57 relative to internal control cells and unstained controls was measured on a FACSCalibur instrument or Fortessa instrument (Becton Dickinson, Franklin Lakes, NJ) to calculate the median telomere length from duplicate measurements. The 99th, 90th, 10th, and 1st percentile curves represent regression curves representative of data ); all measurements were performed in duplicate. The following nucleated blood cell subtypes were analyzed: lymphocytes, granulocytes, CD20
1 B cells
lymphocyte ''memory'' enriched T cells, and CD45RA
1
CD57
1 mature NK and T cells. The ANOVA function in the R language was used to test whether the data were from the same or 2 different model fits to compare the telomere lengths of one population against those of another (ie, patients with CHH vs healthy subjects).
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Lymphocyte cell culture stimulation and telomerase repeat amplification protocol assay
PBMCs were separated by using the Ficoll gradient (GE Healthcare, Fairfield, Conn) and washed, and 0.5 3 10 6 or 1 3 10 6 viable cells were cultured in RPMI 1640 (STEMCELL Technologies, Vancouver, British Columbia, Canada) supplemented with 10% human male AB serum (Sigma, St Louis, Mo). Lymphocytes were stimulated with PHA (1 mg/mL) or immobilized CD3 and CD28 antibodies with or without IL-2 supplementation (100 mg/mL); both PBMC cultures and bead-enriched lymphocyte cell cultures were performed for the second set of samples and were performed in replicates. Viable cell growth was assessed by using trypan blue exclusion with a Vi-CELL XR Counter (Beckman Coulter, Fullerton, Calif) and cell viability analyzer at different culture time points. Equal viable cell numbers were seeded for all patients with CHH and carrier samples on day 1 of culture. Cultured cells were subsequently counted, with minimal disruption at regular intervals corresponding to sampling for accompanying molecular assays (eg, telomere repeat amplification protocol [TRAP] assay on day 13 [day 4] of culture, for instance). Population doublings were calculated during the exponential growth phase of cultures (with adjustment for the sample that showed high initial growth; ie, unique patient number [UPN] 10). After 3 days in culture, 1 3 10 5 viable cells were counted (by using trypan blue exclusion) and lysed to determine telomerase activity levels.
Briefly, telomerase activity from the cellular extracts (after lysis of 1 3 10 5 viable cells at day 13 after lymphocyte stimulation in CHAPS buffer) from 2 3 10 4 or 2 3 10 3 live lymphocyte cell equivalents after in vitro stimulation was tested by using the TRAP assay (Trapeze; Millipore, Temecula, Calif), according to the manufacturer's instructions. PCR was performed as follows: 1 cycle of 958C for 2 minutes, 25 cycles of 948C for 10 seconds, 508C for 30 seconds, 728C for 30 seconds, and 1 cycle of 728C for 5 minutes. Telomere DNA repeat extension products were separated on a 12% native polyacrylamide gel and visualized by means of phosphor-imaging (Molecular Dynamics, Sunnyvale, Calif) for quantification of TRAP signal. Results are representative of duplicate quantifications and are consistent between sample groups from UPN set 2.
RNA extraction, real-time quantitative PCR amplification, and telomerase immunoprecipitation RNA samples were treated with RNase-free DNaseI (Invitrogen, Carlsbad, Calif) to eliminate genomic DNA contamination, and cDNA was prepared with the SuperScript VILO cDNA Synthesis Kit (Invitrogen), according to the manufacturer's instruction. Real-time quantitative PCR (RT-qPCR) was performed with FastStart Universal Probe Master-Rox (Roche) on a 7900 HT Fast Real-Time PCR system instrument (Applied Biosystems, Foster City, Calif). Prime Time q-PCR assays (IDT, Coralville, Iowa) were used for amplification of RMRP, TERT, and telomerase RNA component (TERC) transcripts, with glyceraldehye-3-phosphate dehydrogenase (GAPDH) and ribosomal protein lateral stalk subunit P0 (RPLPO; 36B4) used as endogenous reference genes; PCR reaction efficiencies for all targets were verified to be equivalent for relative quantification. Comparisons between groups were analyzed with the Student t test with Welch correction.
Telomerase immunoprecipitation was performed, as described by Cohen et al, 18 with minor modifications. The sheep polyclonal anti-hTERT antibody and antigen-specific peptide used in immunoprecipitations were kind gifts from S. Cohen and H. Pickett (University of Sydney, Australia). Briefly, viable cultured lymphocytes were counted and harvested by means of centrifugation. Lymphocytes were lysed with ice-cold Lysis buffer A (20 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 0.5% NP-40, 1 mmol/L phenylmethylsulfonyl fluoride, and 1 mmol/L dithiothreitol) at 48C for 30 minutes. Dynabeads Protein G (Novex Life Technologies, Waltham, Mass) were washed and then equilibrated in buffer A (with 0.1 mmol/ L dithiothreitol and 100 ng/mL yeast transfer RNA) while mixing at room temperature for 30 minutes. Partial lysate input was saved to be used as a RT-qPCR normalization control for enrichment calculation. Lysates were incubated with the hTERT antibody at a final concentration of 10 mg/mL at 48C for 30 minutes. Lysates and beads were then incubated for 1 hour at 48C with gentle shaking. Beads were then washed and eluted with TERT-specific peptide and CHAPS or with TRIzol for follow-up TRAP or qPCR assays.
RESULTS
Thymic and T-lymphocyte functions from 5 of the 15 patients with CHH (UPN2, UPN3, and UPN6-UPN8) have been previously reported and demonstrated reduced thymic output, reduced or delayed cell-cycle progression, and a moderate increase in apoptosis 19 compared with healthy subjects. All subjects studied in this report were heterozygous carriers or homozygous for lncRNA RMRP n.70 A>G (see the diagram of RMRP folding prediction in Fig 1   20 ).
Lymphocytes from patients with CHH display delayed or failed proliferative burst on in vitro stimulation
The viability and proliferative capacity of lymphocytes from PBMC cultures of samples from RMRP n.70 A>G heterozygous carrier subjects or RMRP 70A>G homozygous patients with CHH were assessed. Cell viability after PBMC isolation and on culture setup was equivalent for all samples, except those from UPN3 and UPN15 (mean viability of all samples was 67%, with a range from 40% for UPN3 and UPN15 to 80%). Cell viability in cultures over the exponential phase of growth was stable and remained comparable between all samples, including those from UPN3 and UPN15, at days 8 and 10 for sample sets 1 and 2, respectively (mean viability of 79%, with a range of 68% to 86% for sample set 1 and mean viability of 75% with a range of 58% to 85% for sample set 2). The proliferative burst capacity of lymphocytes was examined by using consecutive viable cell count assessment over time with minimal disruption of cultures and is shown in Fig 2, A. Lymphocyte cultures from 11 patients with CHH display a delayed t (5 subjects) or failed (4 subjects) proliferative burst in vitro compared with that of RMRP n.70 A>G heterozygous carrier subjects. This is also illustrated by the comparative population doublings derived from an alternative analysis of the same culture growth data (Fig 2, B) . There was no correlation between cell viability on the day of culture setup and the failure or delay of the proliferative burst (data not shown).
Leukocyte telomere length is impaired in patients with CHH and correlates with immune clinical findings
Three of the patients with CHH tested here had recurrent infections (sinusitis, pneumonia, and otitis media), a fourth presented with autoimmune disease (Table I) , 21 and 6 had impaired vaccine immune response; however, none displayed combined immunodeficiency. Interestingly, for these patients, recurrent infections or autoimmunity, as well as impaired vaccine responses in 2 patients, correlated with very short panlymphocyte telomere length (Fig 3, A, and Table II ). The telomere length of RMRP n.70 A>G heterozygous mutation carriers all lay within the expected 80% healthy subject range of telomere length distribution for all cell subsets tested by using Flow-FISH (Fig 3, A) . These data indicate that a reduction of intact RMRP by 50% does not affect telomere length maintenance in these subjects. By contrast, most patients with CHH with homozygous RMRP mutations tested (11/15) displayed shorter telomere lengths in peripheral blood lymphocytes, with low (at or less than the lower 10% of normal distribution) to very low (5/15 at less than the lower 1% of normal distribution) telomere length. Of note, granulocyte telomere length was also low for 7 of 15 patients with CHH, suggesting that telomere length maintenance might be affected in distinct hematopoietic lineages for a subset of patients with CHH. Similarly, CD45RA
1 CD20 1 B lymphocytes of 7 of 15 patients with CHH had telomere lengths of less than the lower 10% of normal distribution. The statistical model fit for data from these patients differed significantly from that of healthy subjects but remained within the established normal range of distribution for age (Table I) . We calculated the average difference in telomere length to the average normal range age-dependent telomere length (Dtel ,  Table II ) for each group RMRP heterozygous carriers and homozygous RMRP n.70 A>G variant patients with CHH. Taken together, on average, all cell subsets from patients with CHH had 0.7-to 2.2-Kb shorter telomeres than the expected ageadjusted average for healthy subjects. Cells from the T and NK lymphocyte lineages were most severely affected; specifically, CD45RA
1
CD57
1 mature NK or T lymphocytes 22 displayed telomere lengths at or less than the lower 1% of normal distribution for all patients with CHH, with the exception of a single young and a single older adult patient tested. The telomere length statistical model fit of these data was significantly lower than that of healthy subjects (ANOVA, Total TRAP products density (arbitrary units) carriers (open circles) compared with percentile distribution derived from 835 healthy subjects. B and C, Measurement of telomerase activity and semiquantification of total extension products, as well as a heatinactivated control (H) from PBMCs (Fig 3, B) , with comparison to negatively selected lymphocyteenriched (eL) cultures (Fig 3, C) .
Relative TERT or TERC transcript expression in patients with CHH are not affected, but lymphocyte telomerase activity is impaired in a RMRP gene dose-dependent manner
We first assessed the relative transcript expression level of RMRP and telomerase components in samples from RMRP n.70 A>G heterozygous carrier subjects compared with values in RMRP 70A>G homozygous patients with CHH. We found that RMRP relative transcript levels were significantly reduced in patients with CHH compared with those in carrier subjects, as previously reported (P 5.0043 while carriers were not different from healthy subjects; not significant, P 5 .2852). 23, 24 However, relative levels of TERT and TERC transcripts were found to be variable between samples and did not differ significantly between healthy subjects and heterozygous versus homozygous RMRP n.70 A>G patients with CHH (Fig 4) . Similar results were obtained when GAPDH or RPLPO were used as relative expression reference genes (data for RPLPO are not shown).
To determine whether shortened telomeres in patients with CHH could be due to impaired telomerase activity, we measured the holoenzyme activity using the TRAP assay in extracts from PBMCs stimulated in vitro to target T lymphocytes or in extracts from enriched lymphocyte cultures. Compared with telomerase activity of a control extract from healthy subjects, telomerase activity detected in RMRP n.70 A>G heterozygous carrier subjects was reduced but not statistically significantly different (P 5 .1123). A further reduction in activity was seen in RMRP n.70 A>G homozygous patients with CHH (P 5 .048 vs *Difference between the median telomere length of subjects and the regression estimate of the telomere length distribution in healthy subjects of the same age (Dtel). Relative gene expression (to GAPDH)
TERT TERC FIG 4 . Molecular investigation of telomere deficiency in patients with CHH. Triplicate measurements of the relative transcript expression for RMRP, TERT, and TERC relative to GAPDH (error bars represent SDs). The RMRP 70A>G heterozygous sample was set as a reference (light gray bars). Heterozygous (gray bars) and homozygous (black bars) samples were considered as groups for 2-tailed t test comparisons, with a P value of less than .05 considered statistically significant (**). A Significant result was obtained for RMRP only (P 5 .0043).
heterozygous carriers and P 5.0099 vs healthy subjects; Fig 3, B) . Assuming the cellular composition of these extracts was equivalent for sample set 1, these data are indicative of progressive lymphocyte telomerase deficiency among patients with CHH in contrast to carriers and healthy control subjects. This was confirmed by follow-up replication experiments with sample set 2, in which lymphocytes were enriched before the beginning of culture (Fig 3, C) . Telomerase assay results were found to be equivalent for peripheral blood cultures or enriched lymphocyte cultures; enriching for lymphocytes did not improve the activity level of extracts from patients with CHH. These observations suggest the presence of mutant RMRP might result in a decreased global cellular level of nuclear TERT protein, telomerase RNA, or both, therefore limiting functional telomerase holoenzyme activity.
Because it has been previously reported that RMRP binds to the TERT subunit of the telomerase holoenzyme, [7] [8] [9] we investigated the possibility that RMRP n.70 A>G can bind more stably to TERT, effectively outcompeting binding of the telomerase RNA TERC. After immunoprecipitation of TERT, the relative ratio of bound RMRP versus TERC was assessed. Validation of the TERT pulldown experiment was conducted on extracts from the Jurkat lymphocyte cell line before testing primary cultured lymphocytes. This validation showed excellent enrichment of TERC for weak enrichment of RMRP at a ratio of 17 to 1, respectively (see Fig E1 in this article' s Online Repository at www. jacionline.org). The same approach was applied to cell extracts from stimulated primary cell extracts comparing the enrichment ratio of TERC over RMRP pulled down with the anti-TERT antibody from each extract for RMRP n.70 A>G heterozygous carrier subjects and homozygous RMRP n.70 A>G patients with CHH. Single experiments showed the RNA ratios enriched over input did not differ significantly between carrier subjects and patients with CHH, suggesting RMRP n.70 A>G does not outcompete TERC for binding to TERT. Stronger evidence regarding the mechanism involved will need to be investigated in a cellular model system as opposed to primary cultures because of the molecules involved being at or less than the detection limit of these assays in patients with CHH with limiting material available.
DISCUSSION
Patients with CHH display some clinical features that overlap with telomere biology disorders and are particularly susceptible to immune deficiency. Interestingly, both disorders are categorized as diseases with a significant risk of bone marrow failure and have been considered to belong to disease groups, including bone marrow failure syndromes, primary immunodeficiencies, 25 and ribosomopathies. 26 Model studies of CHH have been challenging thus far because of the essential functions of lncRNA RMRP: RMRP was shown to be ubiquitously expressed and was confirmed as an essential lncRNA in early mouse development with failure to generate viable knockout mice, as well as conditional knockout animals. 23, 27 Therefore studies of the consequences of RMRP point mutations from primary patient material have been instrumental in furthering our understanding of the different functions of RMRP and their contribution to disease.
In this study we have investigated the telomere biology parameters, cumulative growth properties, and telomerase molecular parameters in RMRP n.70 A>G heterozygous carriers and homozygous patients with CHH. One advantage of this study is that all subjects studied display the same founder RMRP point mutation, 28 which allowed for examination of a gene dose effect that could be replicated between 2 sample groups. We have observed reduced leukocyte telomere length and lower telomerase activity in stimulated lymphocytes from patients with CHH with the RMRP n.70 A>G mutation. It is interesting to note that because not all peripheral blood cell subsets are equally affected by RMRP deficiency, the telomere length differences observed by using flow-FISH might not have been detected directly by other telomere length measurement methods, as routinely performed. 29 Shorter lymphocyte telomere lengths measured in peripheral blood from patients with CHH compared with age-defined reference values are a novel finding and are consistent with the immunodeficiency, proliferative defects, and increased apoptosis that have been previously documented in patients with CHH 14, 19 compared with carrier or healthy subjects, with carriers not being affected. Also, similar cellular immune findings have been documented in patients with dyskeratosis congenita (in the context of TERC mutation), 30 although correlated with a more severe telomere phenotype than that observed in the present CHH study. The most striking telomere length deficit in samples from patients with CHH was detected in CD45RA 22 and the characteristics of senescent T cells include high CD57 expression, low proliferative capacity, and low telomerase expression after activation. 31 Taken together, these data support that telomere shortening is part of the cellular phenotype of CHH associated with immune senescence. The detection of these cells with shortened telomeres might be a consequence of a very high proliferative demand put on a limiting number of these cells in response to immune challenges. We speculate that unresolved Herpesviridae infection or repeat exposure might contribute to worsening of this phenotype.
Further studies will be helpful to determine whether the telomere cellular phenotypes of other RMRP mutations associated with CHH vary from those observed in the present study and whether they correlate with specific disease phenotypes and immunodeficiency severity. Telomerase activity in lymphocytes is dependent on activation through T-cell receptor stimulation but is not cell-cycle dependent. 11, 12 Because of low cell counts in the samples studied, as well as multiple assays run simultaneously to maximize the data that could be obtained from limiting sample material, we were unable to follow telomerase enzyme activity from extracts at different culture time points. As a result, we could not exclude that telomerase peak activity can be delayed rather than ablated in lymphocytes from patients with CHH after stimulation. However, we were able to confirm that telomerase activity was not significantly different when lymphocytes were negatively selected at the beginning of culture, excluding the possibility that other cell types or varying cell representation influenced the telomerase activity results obtained from CHH cultures. Findings from the present study suggest that the presence of mutant RMRP results in a decreased level of nuclear localized TERT protein, telomerase RNA, or both, thereby limiting functional telomerase holoenzyme activity. Additionally, recent evidence suggests a role for posttranscriptional RNA processing by lnc RMRP, affecting gene regulation in disparate cellular functional pathways involved in CHH, such as skeletal development and hematopoietic cell proliferation, 
